Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Non-Hodgkin Lymphoma Therapeutics Market

Non-Hodgkin Lymphoma Therapeutics Market Share

Report ID: GMI9696
Published Date: May 2024
Report Format: PDF

Download Free Sample

Non-Hodgkin Lymphoma Therapeutics Market Share

The market features leading companies providing a wide array of treatment choices. The players are actively engaged in advancing targeted therapies, immunotherapies, and chemotherapy for Non-Hodgkin lymphoma. The market's growth is propelled by ongoing innovations in therapy development and the investigation of combined treatments to enhance patient results and address resistance mechanisms in treating Non-Hodgkin lymphoma.

Non-Hodgkin Lymphoma Therapeutics Market Companies

Few of the prominent players operating in the Non-Hodgkin lymphoma therapeutics industry include:

Astellas Pharma US, Inc
AstraZeneca PLC
Bayer AG
Bristol Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
GSK plc
F. Hoffmann La-Roche Ltd.
Janssen Pharmaceuticals Inc.
Seagen Inc
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Non-Hodgkin lymphoma therapeutics industry size was worth USD 9.5 billion in 2023 and is projected to expand at 7.4% CAGR from 2024 to 2032, due to the increasing prevalence of non-Hodgkin lymphoma worldwide.

The B-cell lymphomas type segment in the non-Hodgkin lymphoma therapeutics industry is estimated to record USD 9.6 billion by 2032, as these treatments enhance response rates and improve patient outcomes.

The radiation therapy segment in the non-Hodgkin lymphoma therapeutics industry accounted for 45.4% market share in 2023, due to the rising initiatives from key market players, including product launches and partnerships.

U.S. non-Hodgkin lymphoma therapeutics market recorded USD 3.9 billion in 2023 and is anticipated to grow at significant rate between 2024 and 2032, owing to the presence of advanced healthcare infrastructure, robust research and development environment, and substantial investments in cancer therapies.